Traders sold shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on strength during trading hours on Friday following a dissappointing earnings announcement. $0.55 million flowed into the stock on the tick-up and $22.35 million flowed out of the stock on the tick-down, for a money net flow of $21.80 million out of the stock. Of all companies tracked, Karyopharm Therapeutics had the 0th highest net out-flow for the day. Karyopharm Therapeutics traded up $0.74 for the day and closed at $11.23The company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 75.03%.
KPTI has been the subject of a number of analyst reports. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 12th. Jefferies Group LLC restated a “buy” rating and issued a $19.00 price target (up from $16.00) on shares of Karyopharm Therapeutics in a research report on Thursday, August 10th. Canaccord Genuity set a $18.00 price target on Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Tuesday, August 8th. Royal Bank Of Canada restated a “buy” rating and issued a $14.00 price target on shares of Karyopharm Therapeutics in a research report on Wednesday, October 18th. Finally, Robert W. Baird restated a “buy” rating on shares of Karyopharm Therapeutics in a research report on Friday. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $15.38.
In related news, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the transaction, the director now directly owns 2,882 shares in the company, valued at $31,702. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 10,695 shares of company stock worth $118,950 over the last quarter. 14.71% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in KPTI. Wells Fargo & Company MN lifted its holdings in Karyopharm Therapeutics by 114.6% in the first quarter. Wells Fargo & Company MN now owns 43,606 shares of the company’s stock valued at $560,000 after acquiring an additional 23,284 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Karyopharm Therapeutics by 61.7% in the first quarter. Bank of New York Mellon Corp now owns 181,602 shares of the company’s stock valued at $2,332,000 after acquiring an additional 69,315 shares during the last quarter. Swiss National Bank lifted its holdings in Karyopharm Therapeutics by 10.9% in the first quarter. Swiss National Bank now owns 40,850 shares of the company’s stock valued at $525,000 after acquiring an additional 4,000 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in Karyopharm Therapeutics in the first quarter valued at approximately $1,128,000. Finally, Parametric Portfolio Associates LLC lifted its holdings in Karyopharm Therapeutics by 38.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,988 shares of the company’s stock valued at $359,000 after acquiring an additional 7,789 shares during the last quarter. Hedge funds and other institutional investors own 59.10% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
What are top analysts saying about Karyopharm Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Karyopharm Therapeutics Inc. and related companies.